Innoviva (INVA) Expected to Announce Quarterly Earnings on Wednesday

Innoviva (NASDAQ:INVA) is anticipated to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of $0.4360 per share and revenue of $110.9850 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Innoviva (NASDAQ:INVA) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.01. Innoviva had a net margin of 119.89% and a return on equity of 33.33%. The firm had revenue of $97.99 million during the quarter, compared to the consensus estimate of $101.57 million. On average, analysts expect Innoviva to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Innoviva Stock Performance

NASDAQ INVA opened at $20.97 on Monday. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of 3.49 and a beta of 0.34. The company has a debt-to-equity ratio of 0.19, a quick ratio of 20.07 and a current ratio of 21.13. Innoviva has a one year low of $16.52 and a one year high of $25.15. The company’s 50 day moving average price is $22.19 and its 200 day moving average price is $22.26.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Arrowstreet Capital Limited Partnership increased its holdings in Innoviva by 38.1% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,358,633 shares of the biotechnology company’s stock valued at $43,045,000 after buying an additional 650,151 shares during the last quarter. Boston Partners lifted its holdings in Innoviva by 63.6% during the 3rd quarter. Boston Partners now owns 1,431,601 shares of the biotechnology company’s stock worth $26,125,000 after buying an additional 556,517 shares during the last quarter. Qube Research & Technologies Ltd lifted its holdings in Innoviva by 68.2% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,023,534 shares of the biotechnology company’s stock worth $18,679,000 after buying an additional 414,889 shares during the last quarter. UBS Group AG lifted its holdings in Innoviva by 127.2% during the 3rd quarter. UBS Group AG now owns 572,368 shares of the biotechnology company’s stock worth $10,446,000 after buying an additional 320,499 shares during the last quarter. Finally, Marshall Wace LLP grew its position in shares of Innoviva by 23.9% in the 3rd quarter. Marshall Wace LLP now owns 1,651,711 shares of the biotechnology company’s stock worth $30,144,000 after acquiring an additional 318,745 shares in the last quarter. 99.12% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently issued reports on INVA. HC Wainwright reissued a “buy” rating and issued a $46.00 price objective on shares of Innoviva in a research report on Monday, June 1st. Wall Street Zen lowered shares of Innoviva from a “buy” rating to a “hold” rating in a report on Saturday. BTIG Research reaffirmed a “buy” rating and set a $42.00 price target on shares of Innoviva in a research report on Monday, June 22nd. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Innoviva in a report on Wednesday, June 24th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $36.20.

Innoviva Company Profile

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.